Results

1–2 of 2 results for Robert C. Wang

Safety and Efficacy of Brepocitinib, a TYK2/JAK1 Inhibitor, in Active Non-Infectious Uveitis: 24-Week Results from a 52-Week Phase 2 Study (NEPTUNE)
Robert C. Wang, MD, FASRS
Annual Meeting Talks
2024
Deferred Compensation? Tax Cuts and the Jobs Act What You Need to Know
Robert C. Wang, MD, FASRS
Updates from the Field
2018